Order results by:
| Issue | Title | |
| Vol 8, No 4 (2016) | GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS | Abstract similar documents |
| T. E. Shmidt | ||
| "... acetate is one of the MSMDs of first choice and has a dual (anti-inflammatory and neuroprotective) action ..." | ||
| Vol 8, No 2 (2016) | Glatiramer acetate 40 mg/ml: A review of the results of GALA and GLACIER clinical studies | Abstract similar documents |
| N. Yu. Lashch, A. N. Boiko | ||
| "... reviews the main GALA (Glatiramer Acetate Low-frequency Administration) and GLACIER (Glatiramer Acetate ..." | ||
| Vol 13, No 1S (2021): Спецвыпуск: рассеянный склероз | Attitude to reproduced disease modifying therapies in patients with relapsing-remitting multiple sclerosis: results of a medical and sociological study | Abstract similar documents |
| Ya. V. Vlasov, M. V. Churakov, E. V. Sineok, A. N. Boyko | ||
| "... , glatiramer acetate, and teriflunomide, who had an experience of switching from an original drug to a domestic ..." | ||
| Vol 7, No 1 (2015) | Non-biological complex drugs and their analogues in the pathogenetic therapy of multiple sclerosis: Issues of efficacy and safety in clinical use | Abstract similar documents |
| I. D. Stolyarov, A. M. Petrov, M. V. Votintseva, I. G. Nikiforova | ||
| "... of multiple sclerosis (MS) – glatiramer acetate (GA, Copaxone®, Teva) in large Russian MS centers ..." | ||
| Vol 7, No 3 (2015) | Pharmacoeconomic analysis of the use of first- and second-line drugs in the treatment of multiple sclerosis | Abstract similar documents |
| V. R. Mkrtchyan, L. V. Brylev, O. V. Davydova, A. V. Belyanin, I. A. Shpak, A. M. Sergeev | ||
| "... ), subcutaneous glatiramer acetate (copaxone, 20 mg), intravenous natalizumab (tyzabri, 300 mg), and oral ..." | ||
| Vol 16 (2024): (Suppl. 2) | Sampeginterferon beta-1a in clinical practice | Abstract similar documents |
| I. A. Sokolova, O. S. Kornakova, E. V. Sokolova | ||
| "... initially received glatiramer acetate as DMT, which led to exacerbations and an increase in neurological ..." | ||
| Vol 9, No 1 (2017) | Clinical and epidemiological features of patients with multiple sclerosis in the Kursk Region | Abstract similar documents |
| V. B. Laskov, E. A. Logacheva, E. E. Tretyakova, M. A. Gridnev | ||
| "... characteristics in the region. The pattern of disability was studied in patients. Glatiramer acetate ..." | ||
| Vol 7, No 1S (2015): Special issue "Epilepsy" | Epilepsy in patients with multiple sclerosis: specific features of diagnosis and therapy | Abstract similar documents |
| Yu. A. Belova, T. I. Yaukushina, I. G. Rudakova, S. V. Kotov | ||
| "... untreated for MS; 7 took MS-modifying drugs: interferonβ1a (n=2) or glatiramer acetate (n=5). The course ..." | ||
| Online-first | The first experience with the use of ofatumumab for the treatment of pediatric multiple sclerosis in real-life clinical practice in Russia. A case series | Abstract similar documents |
| E. D. Kuzminykh, V. M. Lebedev, V. E. Senchenko, M. S. Cherepyansky, V. A. Gonchar, D. S. Korobko | ||
| "... with a four-year history of the disease showed resistance to first-line therapy (interferon β1a and glatiramer ..." | ||
| Vol 17, No 1 (2025) | The first experience with the use of ofatumumab for the treatment of pediatric multiple sclerosis in real-life clinical practice in Russia. A case series | Abstract similar documents |
| E. D. Kuzminykh, V. M. Lebedev, V. E. Senchenko, M. S. Cherepyansky, V. A. Gonchar, D. S. Korobko | ||
| "... with a four-year history of the disease showed resistance to first-line therapy (interferon β1a and glatiramer ..." | ||
| Vol 8, No 4 (2016) | USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS | Abstract similar documents |
| V. R. Mkrtchyan, L. V. Brylev, I. A. Shpak, A. M. Sergeev | ||
| "... in a cost-effectiveness ratio and to be slightly ahead of the MS-modifying drugs (MSMDs) and the second ..." | ||
| Vol 12, No 3 (2020) | Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis | Abstract similar documents |
| K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. V. Davydovskaya, M. N. Zakharova, N. A. Malkova, A. I. Nilov, S. A. Sivertseva, N. N. Spirin, N. A. Totolyan, F. A. Khabirov, M. V. Shumilina | ||
| "... -modifying drugs (MSMDs) or there is ≥1 exacerbation and corresponding activity signs revealed by MRI during ..." | ||
| Vol 11, No 4 (2019) | Current requirements for studies of drugs for the pathogenetic treatment of multiple sclerosis | Abstract similar documents |
| A. N. Boyko, N. N. Spirin, Ya. V. Vlasov, M. N. Zakharova | ||
| "... More than 10 multiple sclerosis-modifying drugs (MSMDs) are widely used now. Novel MSMDs should ..." | ||
| 1 - 13 of 13 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
